Abstract:1299 Since 1977, numerous studies have indicated the existence of a putative membrane-based estrogen receptor. However, the identity of this membrane-based estrogen receptor has not been established. Through an extensive homology search in Gene Bank, we recently identified and cloned a novel variant of ER-Α with a predicted molecular weight of 35.7 kDa. The transcript of this ER-Α variant is initiated from a previously unidentified promoter in the first intron of the original ER-Α gene. This ER-Α variant differs from the original ER-Α by lacking both transcriptional activation domains (AF-1 and AF-2) but retaining the dimerization, DNA-binding and partial ligand-binding domains. Its ligand-binding domain also possesses a unique 27 amino acid stretch that replaces the last 138 amino acids of the ER-Α. In transient transfection assays, this ER-Α variant exhibited no intrinsic transcriptional activity but strongly inhibited ligand-dependent and -independent transactivation activities mediated by the original ER-Α and ER-Β. Immunodetection and subcellular fractionation assays demonstrated that this ER-Α variant is expressed on the plasma membrane of mammary epithelial cells, and also in the cytoplasm and nucleus. In cells that express this ER-Α variant, 17Β-estradiol (E2) treatment activated a membrane-initiated effect of estrogen signaling by transiently activating the mitogen-activated protein kinase (MAPK) pathway that led to cell proliferation. Antiestrogens such as tamoxifen and ICI 182,780, however, strongly and persistently activated the MAPK pathway that then resulted in activation of the SAPK/JNK pathway. Immunohistochemistry analysis using a specific antibody aganst this ER-Α variant revealed that 26 of 38 cases (68%) breast cancer specimens examined express this ER-Αvariant on the plasma membrane and cytoplasm, and 12 out of 13 ER-negative breast caner specimens also express this ER-Α variant. Our findings demonstrate a physiologically important ER-Α variant that is involved in membrane-initiated estrogen signaling and suggest that aberrant expression of this ER-Α variant contributes to development of ER-positive and-negative human breast cancer.

Isolation and Characterization of Proteins Interacting with Estrogen Receptor Β

Isolation and analysis of a novel co-regulator of estrogen receptor beta

Identification of A Novel Estrogen Receptor Beta 1 Binding Partner, Inhibitor of Differentiation-1, and Role of Er Beta 1 in Human Breast Cancer Cells

Isolation of an ERβ-interacting Protein PSMC5 and Its Role in ERβ Signaling

Isolation of an ERβ interaction protein HPIP and its role in ERβ singnaling

Estrogen Receptor Interacts with Collagen Ⅰ

[Isolation and Characterization of a BRCA1-interacting Protein].

A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Identification, Cloning, and Expression of Human Estrogen Receptor-Α36, a Novel Variant of Human Estrogen Receptor-Α66

A Bipartite Recombinant Yeast System for the Identification of Subtype-Selective Estrogen Receptor Ligands

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

The expressing signification of estrogen receptorβ in breast cancer

Screening of Proteins Interacting with Hprb by Yeast Two Hybrid

Selective Ligands of Estrogen Receptor Β Discovered Using Pharmacophore Mapping and Structure-Based Virtual Screening.

Interaction between insulin-like growth factors Ⅰ receptor and estrogen receptor induced by estradiol and insulin-like growth factors Ⅰ

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

Interaction Between Igf-Ir And Er Induced By E2 And Igf-I

Expression of human estrogen receptor α and β in Escherichia coli

XBP-1 interacts with estrogen receptor alpha (ERalpha)]

Identification and Characterization of Two Novel Splicing Isoforms of Human Estrogen-Related Receptor Beta

Research Advance on a Novel Estrogen Receptor β